GENIUS-CHD aims to be an open, global and all inclusive consortium with transparent operating and governance procedures.
Cohorts or studies are invited to join if they are eligible according to the following 3 criteria
(1) Collection of subjects with established coronary heart disease. This can be stable CHD (patients with revascularization, stable symptoms with confirmed CAD) or acute CHD (including but not limited to ACS at enrollment or prior MI) or a mixture (such as angiographic collections).
Studies can be either investigator led clinical cohorts, nested case-cohorts or large RCTs.
(2) Stored biological samples. As the consortium seeks to identify biomarkers and genetic variants of risk, studies must have collected blood or tissue samples at enrollment. These samples need not have been already processed, but should be available for any future biomarker or genetic analysis.
A key aim of GENIUS-CHD is to leverage funding so that cohorts with stored samples can be funded to start genotyping or biomarker analysis.
(3) Prospective follow up. All study participants should be followed for subsequent events. The types of outcomes will vary by study, but as a minimum we expect cohorts to collect all cause mortality and or MI.
Many studies may not have long enough follow up yet, but these are still eligible to join as follow up will mature with time.
If you have a cohort that meets these criteria, and would like to join or learn more please get in touch through the contact us page.